Lecanemab licensed for adult patients in the early stages of Alzheimer’s disease

Twitter

Linkedin

Facebook

email

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 22 August 2024, approved a product licence for the medicine lecanemab (Leqembi) for use in the early stages of Alzheimer’s disease, following a thorou…

Follow this news feed: